Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate

依非韦伦/拉米夫定/富马酸替诺福韦二吡呋酯

Report date: 2026/04/08 20:02:35

Base Information

Drug NameEfavirenz/Lamivudine/Tenofovir Disoproxil Fumarate
Drug Alias Name拉米夫定依非韦伦富马酸替诺福韦二吡呋酯Efavirenz/Lamivudine/TenofovirEfavirenz/Lamivudine/Tenofovir Disoproxil依非韦伦/富马酸替诺福韦二吡呋酯/拉米夫定依非米替 +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHuman immunodeficiency virus type 1 reverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2018/02/05
Country/TerritoryUnited StatesThailandMainland China
CombinationsYes EfavirenzLamivudineTenofovir Disoproxil Fumarate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMylan Nv
China Registration ClassN/A

Develop Information

Active CompaniesViatris Pharmaceuticals Co Ltd
Inactive CompaniesMylan LaboratoriesMylan Nv
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR11
Related LinksWikipedia